Abstract
Osteopontin is an extracellular matrix protein that is upregulated in renal injury. The aim of this study was to explore the renal expression of osteopontin in a model of progressive renal injury following subtotal nephrectomy (STNx) in rats and the effects of angiotensin type1 (AT1) receptor antagonist irbesartan on osteopontin expression. STNx or a sham operation was performed in 8-week-old Sprague-Dawley rats. STNx rats were given either irbesartan (15 mg/g) or no treatment for 12 weeks. Upregulation of osteopontin mRNA expression was observed in injured renal tubules as assessed by in situ hybridization (42 ± 8 dpm/mm2 v.s. control 7.7 ± 0.6 dpm/mm2, p < 0.01). Increased osteopontin expression was closely related to infiltration of monocytes/macrophages and increased cellular proliferation. Double immunohistochemical staining demonstrated co-existence of proliferating cell nuclear antigen and osteopontin positive staining in individual cells in kidney sections from STNx rats. The increase in osteopontin expression was inhibited by the AT1 receptor antagonist irbesartan (6.9 ± 1.2 dpm/mm2), associated with attenuation of impaired renal function and pathology as well as decreased monocyte/macrophage infiltration and cellular proliferation. These findings suggest that osteopontin is upregulated in STNx rats and is reduced by AT1 receptor antagonism.
References
1.
Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrology 1998;9:224–230.
2.
Diamond JR, Kreisberg R, Evans R, Nguyen TA, Ricardo SD: Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int 1998;54:1501–1509.
3.
Giachelli C, Bae N, Lombardi D, Majesky M, Schwartz S: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun 1991;177:867–873.
4.
Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998;152:353–358.
5.
Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 1997;51:1553–1567.
6.
Buñag RD: Validation in awake rat of a tail-cuff method for measurement of systolic blood pressure. J Appl Physiol 1973;34:279–282.
7.
Lott JA, Stephan VA, Pritchard KJ: Evaluation of the Coomassie Brilliant blue G-250 method for urinary protein. Clin Chem 1983;29:1946–1950.
8.
Cao Z, Dean R, Wu L, Casley D, Cooper ME: Role of angiotensin receptors subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension 1999;34:408–414.
9.
Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995;43:97–102.
10.
Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994;45:515–524.
11.
Rumble JR, Cooper ME, Soulis T, Cox A, Wu L, Youssef S, Jasik M, Jerus G, Gilbet R: Vascular hypertrophy in experimental diabetes; role of advanced glycation end products. J Clin Invest 1997;99:1016–1027.
12.
Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, Johnson RJ: Tubulointerstitial disease in glomerulonephritis – potential role of osteopontin (uropontin). Am J Pathol 1994;144:915–926.
13.
Ophascharoensuk V, Giachelli CM, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland SJ, Alpers CE, Couser WG, Johnson RJ: Obstructive uropathy in the mouse: Role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999;56:571–580.
14.
Lan HY, Yu XQ, Yang NS, Nikolicpaterson DJ, Mu W, Pichler R, Johnson RJ, Atkins RC: De novo glomerular osteopontin expression in rat crescentic gomerulonephritis. Kidney Int 1998;53:136–145.
15.
Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, Shankland SJ, Alpers CE, Bennett WM, Couser WG, Johnson RJ: Pathogenesis of cyclosporine nephropathy – roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995;6:1186–1196.
16.
Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA: Osteopontin is produced by rat cardiac fibroblasts and mediates a(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218–2227.
17.
Kleinknecht C, Terzi F, Burtin M, Laouari D, Maniar S: Experimental models of nephron reduction: Some answers, many questions. Kidney Int 1995;47:S51–54.
18.
Kliem V, Johnson RJ, Alpers CE, Yoshimura A, Couser WG, Koch KM, Floege J: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996;49:666–678.
19.
Deblois D, Lombardi DM, Su EJ, Clowes AW, Schwartz SM, Giachelli CM: Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension 1996;28:1055–1063.
20.
Wolf G: Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 1998;24:174–180.
21.
Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM: Osteopontin regulation in cultured rat renal epithelial cells. Kidney Int 1997;51:1766–1773.
22.
Eddy AA, Giachelli CM, McCulloch L, Liu E: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546–1557.
23.
Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME: Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 1999;56:601–611.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
